J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks

A look at the company’s pipeline shows that Oculis has several drug candidate programs undergoing late-stage clinical studies. One is OCS-01, a potential treatment for DME. This condition is a leading cause of preventable blindness in adults, and affects over 37 million people around the world – that number is expected to rise to 53 million by 2040. Current treatments are invasive, involving ocular implants or direct intravitreal injections – these invasive modes directly and negatively impact patient compl ...